

Post-*iwCLL* Congress Highlights: CLL Podcast (GB-73501)

References:

1. Angotzi F, et al. Unravelling the Clinical and Biological Features of Accelerated Chronic Lymphocytic Leukemia. *iwCLL 2025*; 12-15 September 2025; Krakow, Poland. Poster 1022.
2. Gordon BK, et al. Targeting BTKi-Resistant CLL Using the Dual Irreversible/Reversible 4th Generation BTK Inhibitor Rocbrutinib. *iwCLL 2025*; 12-15 September 2025; Krakow, Poland. Poster 1801.
3. Lind O, et al. Early effects of Venetoclax monotherapy on immune cells in patients with CLL. *iwCLL 2025*; 12-15 September 2025; Krakow, Poland. Poster 1209.
4. Slanger S, et al. Insights into Pathogenesis from Germline Predisposition/Familial CLL studies, including MBL. *iwCLL 2025*; 12-15 September 2025; Krakow, Poland.
5. Koren-Michowitz M, et al. Central Nervous System Involvement in Chronic Lymphocytic Leukemia: An International Retrospective Study by ERIC, the European Research Initiative on CLL. *iwCLL 2025*; 12-15 September 2025; Krakow, Poland. Poster 1438.
6. Yoon JT, et al. Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia. *Blood Adv* (2025) 9 (11): 2808–2817.
7. Samples L, et al. Clinical Outcomes in Patients Treated with Both Covalent Btkis and Venetoclax and the Significance of “Double-Refractory” Status in Patients with CLL/SLL. *Blood* (2023) 142 (Supplement 1): 4650.
8. Davids MS, et al. ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia. *Blood* (2021) 138 (Supplement 1): 2634.